Browse articles from EyeWorld.org related to glaucoma. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Combination pharmaceutical therapy being investigated for presbyopia meets study endpoints ➤ Positive results in Phase 2 clinical trial for IOP-lowering agent ➤ Phase 3 results from study of gene therapy for retinal neurodegenerative diseases ➤ Positive safety results in Phase 1 anti-VEGF treatment ➤ ASCRS news and events
➤ Investigational gene therapy for choroideremia does not meet study endpoints ➤ Positive safety results in Phase 1/2a clinical trial of investigational drug for wet AMD ➤ Patient enrollment complete for Phase 3 clinical trial of sustained-release travoprost implant ➤ Two companies enter collaboration to develop, commercialize ocular surface disease therapies ➤ ASCRS events
ASCRS Subspecialty Day will take place on Friday, July 23, and will include the ASCRS Refractive Day, ASCRS Cornea Day, and ASCRS Glaucoma Day programs. The chairs of these programs spoke to EyeWorld about what attendees can expect.
Richard Lewis, MD, will give this year’s Binkhorst Lecture during the Opening General Session at the ASCRS Annual Meeting. His lecture is titled “We Can Prevent Blindness in Glaucoma—Why Don’t We?”
Ophthalmology will see its first major live meeting since the pandemic started with the 2021 ASCRS Annual Meeting. “Just as the live meeting will be reflective of our interesting times, this issue of EyeWorld is a product of our unique year, covering many topics that will help the modern ophthalmologist and glaucoma specialist succeed,” said Nathan Radcliffe, MD, Glaucoma editor.
Glaucoma should not necessarily be an immediate contraindication to premium cataract surgery technologies, such as toric and presbyopia-correcting IOLs and FLACS. Reay Brown, MD, Paul Harasymowycz, MD, and Joey Hsia, MD, said there are situations where these IOL technologies are suited for glaucoma patients, but the decision to offer them is not as straightforward.
Some MIGS options are approved only in conjunction with cataract surgery, while others are not limited in this way. Three ophthalmologists EyeWorld spoke with think there is a value in uncoupling some MIGS procedures from cataract surgery, yet two of the three do not perform off-label standalone MIGS.
Infection is a risk for any ocular surgery, but there are a few reasons why there isn’t a lot of discussion about infection when it comes to glaucoma procedures. MIGS, which have become increasingly common, have a lower infection risk profile compared to incisional glaucoma surgery.
➤ Results from Phase 1 clinical trial of intranasal glaucoma drug ➤ Phase 3 clinical trial of new ophthalmic corticosteroid nanoemulsion ➤ Pharmaceutical company expands gene therapy pipeline ➤ Companies enter agreement to develop next-generation decision support software ➤ Study: Association between caffeine intake and glaucoma
➤ FDA grants De Novo authorization for new intense pulsed light device ➤ Post-approval study requirements fulfilled for clear corneal incision sealant ➤ Interim analysis for acute adenoviral conjunctivitis drug ➤ NDA resubmission for injection to treat macular edema associated with uveitis ➤ FDA approves abbreviated NDA for glaucoma drug ➤ Study: Functional and psychosocial impact of Demodex blepharitis ➤ Next ASCRS Journal Club on May 13